Newron Pharmaceuticals S.p.A. (LON:0QOI)

Market Cap	372.16M +128.9%
Revenue (ttm)	51.33M +759.1%
Net Income	21.71M
EPS	1.02
Shares Out	n/a
PE Ratio	17.14
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	970
Average Volume	22,270
Open	19.64
Previous Close	19.33
Day's Range	19.56 - 19.88
52-Week Range	5.34 - 31.85
Beta	0.70
RSI	42.23
Earnings Date	Mar 24, 2026

About Newron Pharmaceuticals

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson’s in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company’s lead compound includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III cl...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1999
• Employees: 22
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QOI

Financial Performance

Financial numbers in EUR